Norstella’s Real-World Data/AI Executive Forum Highlights
The Norstella Real-World Data Executive Forum explores how real-world data (RWD) can accelerate treatment progress in neuro-oncology, particularly for small patient populations and rare subgroups whose outcomes take years to fully measure. Norstella’s mission to “smooth the path to life-saving therapies” guides its RWD strategy, including curating data elements that closely mirror clinical trial inclusion […]
Norstella and Replit Team Up to Accelerate Innovation and Optimize Commercial Processes with AI
Innovation at Norstella often begins with a question: What if we could move faster—without sacrificing quality or compliance? During a recent hackathon, Norstella’s commercial and product teams had a chance to answer that question firsthand and help us drive our mission of improving patient access to lifesaving therapies across the drug development cycle by using […]
The Convergence of AI and Real-World Data are Reshaping Clinical Trials
As clinical trials increase in number and complexity, so does the competition for the patients best aligned to the study requirements. And with clinical trial processes relatively unchanged over the past decades, a patient and investigator bottleneck has emerged. Finally, with the convergence of artificial intelligence and algorithms trained on real-world data (RWD) sources, we […]
Inside Norstella’s Innovation Engine: How the Next Generation of Real-World Data Gets You Closer to the Patient
Real-world data (RWD) is transforming the life sciences industry, giving pharma companies valuable insights into the patient journey and helping more people get the life-saving treatments they need. To discuss the power of real-world data, where it’s headed, and how it’s fueling Norstella’s next generation of product development, we caught up with Kris Kaneta, Chief […]
Conference Catch-Up: Innovation, AI & the Future of Pharma Deal-Making
In this episode, we recap the key takeaways from BIO-Europe 2025, held in Milan, Italy, in March 2025, with Trajko Spasenovski, Vice President of Strategic Account Management at Evaluate, and Carolyn Hall, Senior Director of Content and Thought Leadership Marketing at Evaluate. After the conference, Citeline’s Managing Editor, Meredith Landry, spoke with them about their […]
How Unstructured EMR Data Helps Pharma Find Patients
As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key limitations is the lack of timeliness. Many manufacturers now rely on specialized lab data—from imaging results to genetic testing and genomics—to identify eligible patients and […]
Connecting the Dots with NorstellaLinQ
Norstella’s VP of thought leadership, Daniel Chancellor, was invited to share his perspectives on the proliferation of data with the leading publication The Medicine Maker. The timing was perfect, coming shortly after we launched NorstellaLinQ, the biopharma industry’s first fully integrated data asset. The article explores various themes such as abundance, the importance of data […]
Breaking Barriers in Rare Disease Drug Development
Bringing rare disease treatments from pipeline to patient Rare diseases affect more than 395 million people worldwide, yet only 5% have an FDA-approved treatment. The challenges of small patient populations, regulatory complexities, and limited clinical data have historically slowed progress. But the landscape is changing. This infographic explores the key barriers in rare disease drug […]
Assessing Current AI Trends in Drug Development: Operational Efficiency and Overcoming Challenges (Part 2)
Artificial intelligence (AI) has shifted from experimental projects to a valuable pharmaceutical research and development (R&D) asset. While the pace of adoption varies across the industry, AI is enabling organizations to address inefficiencies, reduce timelines, and improve decision-making at critical drug development stages. Building on the insights from part 1, which highlighted how companies are […]
Complex Cohort Identification Fuels Real-Time HCP Targeting
A large manufacturer preparing for the launch of its new oncology therapy sought a deeper understanding of the specific disease state. The company’s market access team wanted to track specialist referral patterns and determine the average time between diagnosis and treatment. The manufacturer also needed to identify patients who were potentially eligible for its product, […]
